Sun Pharma Advanced Research Company Ltd received a favourable verdict from the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai. The tribunal upheld the refund of ₹2,751 lakh in accumulated CENVAT credit along with consequential interest.

This decision confirms the company's entitlement to the refund and dismisses the Revenue's appeal against the earlier order. The litigation, which was disclosed as a continuing event in August 2023, now stands decided in favour of the company.

Litigation background and outcome

The dispute pertained to the accumulation of CENVAT credit, a mechanism allowing manufacturers to offset excise duty paid on inputs. The CESTAT upheld the Order-in-Appeal dated April 27, 2018, which had previously ruled in favor of the company.

The company filed an intimation under Regulation 30 of the SEBI Listing Regulations to inform stock exchanges about this development. The update clarifies that no settlement terms or penalties were applicable, as the matter was resolved through a judicial ruling rather than a negotiated settlement.

Key details of the tribunal order

The following table summarizes the key aspects of the litigation update disclosed to the National Stock Exchange and BSE:

What the numbers show

The confirmation of ₹2,751 lakh represents a direct recovery of previously blocked tax credits. For a mid-cap pharmaceutical entity, this amount constitutes a significant one-time cash inflow that improves liquidity without impacting operational revenue lines. The dismissal of the Revenue's appeal removes a contingent liability risk that had been on the balance sheet since at least 2018.

Sun Pharma Advanced Research Company Limited reported a standalone net loss of ₹2,098 lakhs for the quarter ended June 30, 2026, compared to a net loss of ₹5,203 lakhs in the corresponding quarter of FY26. While the loss narrowed in absolute terms, revenue from operations surged 314% year-on-year to ₹3,992 lakhs, primarily due to one-time income from a terminated licensing agreement rather than organic growth in pharmaceutical research activities.

The Board of Directors approved the unaudited financial results at its meeting held on August 10, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditor, S R B C & Co LLP. Additionally, the Board approved requests for the reclassification of certain promoter group individuals from the "Promoter Group" category to the "Public" category, subject to necessary approvals under Regulation 31A of the Listing Regulations.

Financial Performance Overview

Total revenue from operations stood at ₹3,992 lakhs in Q1FY27, up significantly from ₹964 lakhs in Q1FY26. This increase was largely attributable to the recognition of ₹2,921 lakhs in revenue relating to non-refundable consideration following the mutual termination of a licensing agreement with CMS Bridging DMCC ("CMS"). The company refunded USD 2 million (₹1,889 lakhs) to CMS as part of this settlement. Excluding this one-time item, recurring revenue from contracts with customers remained modest at ₹3,992 lakhs total, indicating that operational cash flows are still heavily dependent on such strategic exits or grants.

Expenses totaled ₹8,456 lakhs, an increase of 19.6% from ₹7,069 lakhs in the previous year. Employee benefits expense rose to ₹2,416 lakhs from ₹2,768 lakhs, while clinical trial and product development expenses increased to ₹1,326 lakhs from ₹554 lakhs. Professional charges declined to ₹2,124 lakhs from ₹1,436 lakhs. Finance costs remained relatively stable at ₹813 lakhs.

What the Numbers Show

The divergence between the sharp rise in revenue and the continued net loss highlights the structural cost base of the company’s research operations. While the termination of the CMS agreement provided a significant revenue boost, it did not offset the ongoing burn rate associated with clinical trials and professional services. The narrowing of the net loss is thus a function of both higher one-time income and a slight moderation in certain expense categories, rather than a fundamental improvement in operating margins. Investors should note that the prior year’s figures included an exceptional item of ₹1,236 lakhs related to new labour codes, which is not present in the current quarter, making the direct comparison of pre-tax losses slightly distorted by this non-recurring prior-year charge.

Consolidated Results

On a consolidated basis, which includes subsidiaries SPARCLIFE, Inc. and Genokine Biotech Limited, the group reported a net loss of ₹2,078 lakhs for Q1FY27, compared to a loss of ₹5,187 lakhs in Q1FY26. Consolidated revenue from operations was also ₹3,992 lakhs. The consolidated results reflect similar trends, with employee benefits expense rising to ₹2,961 lakhs and professional charges decreasing to ₹1,519 lakhs. Tax expense was minimal at ₹11 lakhs.

Other Developments

The company noted that during the quarter ended March 31, 2026, it recognized income of ₹184,002 lakhs regarding a Priority Review Voucher (PRV) granted by the USFDA for Sezaby®. The PRV was sold on April 30, 2026, for USD 195 million. This significant past-quarter event underscores the company’s strategy of monetizing regulatory assets to fund its R&D pipeline. Furthermore, on May 19, 2026, the company allotted 3,85,10,000 warrants to Shanghvi Finance Private Limited at an issue price of ₹155.80 each, raising capital to support future operations.